Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$371 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-18.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
22.7
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.3
Face value
--
Shares outstanding
86,320,000
CFO
$-221.70 Mln
EBITDA
$-305.13 Mln
Net Profit
$-318.32 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Checkpoint Therapeutics (CKPT)
| 33.1 | 3.9 | 57.2 | 132.8 | -32.9 | -27.5 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Checkpoint Therapeutics (CKPT)
| 39.4 | -55.2 | -83.6 | 17.4 | 54.1 | -5.5 | -52.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and... internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with Dana-Farber Cancer Institute, Inc. Checkpoint Therapeutics, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts. As of May 30, 2025, Checkpoint Therapeutics, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited. Read more
President, CEO & Director
Mr. James F. Oliviero III, C.F.A.
President, CEO & Director
Mr. James F. Oliviero III, C.F.A.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Checkpoint Therapeutics Inc (CKPT) is $4.26 (NASDAQ) as of 30-May-2025 16:00 EDT. Checkpoint Therapeutics Inc (CKPT) has given a return of -32.9% in the last 3 years.
Since, TTM earnings of Checkpoint Therapeutics Inc (CKPT) is negative, P/E ratio is not available.
The P/B ratio of Checkpoint Therapeutics Inc (CKPT) is 22.75 times as on 30-May-2025, a 477 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-2.26
|
-10.06
|
|
2023
|
-1.21
|
-4.79
|
|
2022
|
-0.79
|
-2.70
|
|
2021
|
-0.43
|
0.82
|
|
2020
|
-0.65
|
0.42
|
The 52-week high and low of Checkpoint Therapeutics Inc (CKPT) are Rs 4.50 and Rs 1.80 as of 03-Apr-2026.
Checkpoint Therapeutics Inc (CKPT) has a market capitalisation of $ 371 Mln as on 30-May-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Checkpoint Therapeutics Inc (CKPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.